Scrip's Complete Guide to CNS Disorders

Scrip's Complete Guide to CNS Disorders

Therapeutic

A comprehensive overview of the global market for current and forthcoming CNS drugs, this report covers the major areas: Alzheimer's disease, Parkinson's disease, depression, schizophrenia and anxiety. Six volumes supply you with invaluable information on CNS drugs in R&D and the global market for CNS therapies.

Access:

Extensive R&D information on over 150 products in clinical trials for CNS disorders
R&D details for over 200 drugs in preclinical research
Relative market share of products and sales forecasts to 2002 for each disease
18 top company profiles
Sales figures for the top 30 CNS drugs currently on the market

Each major disease area is covered in a separate volume containing definitions, pathogenesis, risk factors and epidemiology. The report also supplies descriptions of current treatments and information on their advantages and disadvantages.

Profiles of the 18 companies most active in the CNS field allow you to undertake accurate competitor analysis - and evaluate opportunities for strategic collaborations.

PUBLISHED: AUGUST 1999
REF: BS1023E
PAGES: 600+
PRICE: Complete six-volume set �990/$1,995/�238,000

For more information or details on individual volume pricing, please contact our Customer Helpdesk:
Tel +44 (0)20 8332 8965/66
Fax +44 (0)20 8332 8992

CONTENTS
LIST OF TABLES
LIST OF FIGURES
ACKNOWLEDGEMENTS
EXECUTIVE SUMMARY
METHODOLOGY
ABBREVIATIONS
GLOSSARY

CHAPTER 1 INTRODUCTION
1.1 Background
1.2 Definitions
1.2.1 Idiopathic Parkinson's disease
1.2.2 Early-onset Parkinson's disease
1.2.3 Late-onset Parkinson's disease
1.2.4 Secondary forms of Parkinson's disease
1.3 Symptoms
1.3.1 Primary symptoms
1.3.2 Secondary symptoms
1.4 Pathogenesis
1.4.1 Dopamine synthesis, action and metabolism
1.4.2 Dopaminergic changes in Parkinson's disease
1.4.3 Opportunities for drug intervention
1.4.4 Aetiology
1.4.4.1 Genetic factors
1.4.4.2 Environmental factors
1.5 Risk factors
1.5.1 Age
1.5.2 Gender
1.5.3 Geographical region and level of development
1.6 Epidemiology
1.6.1 Incidence
1.6.2 Prevalence
1.6.3 Age of onset
1.7 Prognosis
1.8 Trends in treatment
1.8.1 Dopaminergic treatments
1.8.2 Monoamine oxidase inhibitors
1.8.3 COMT inhibitors
1.8.4 Anticholinergic treatments
1.8.5 Course of treatment
1.9 Treatments other than drug therapy

CHAPTER 2 MARKETED DRUGS
2.1 Summary of drug classes
2.2 Dopaminergic drugs
2.2.1 Agents enhancing basal dopamine levels or replacing dopamine
2.2.1.1 Levodopa
2.2.1.2 Levodopa + benserazide
2.2.1.3 Carbidopa + levodopa (co-careldopa)
2.2.2 Dopamine agonists
2.2.2.1 Apomorphine
2.2.2.2 Bromocriptine
2.2.2.3 Cabergoline
2.2.2.4 Pergolide
2.2.2.5 Pramipexole
2.2.2.6 Ropinirole
2.2.2.7 Talipexole
2.2.2.8 Terguride
2.2.3 Inhibitors of monoamine oxidase
2.2.3.1 Selegiline
2.3 COMT inhibitors
2.3.1 Entacapone
2.3.2 Tolcapone
2.4 Modulators of excitatory amino acid transmission and neuroprotection
2.4.1 Memantine
2.4.2 (-dihydroergocryptine
2.5 Others
2.5.1 Budipine
2.6 Summary of marketed drugs
2.7 Opportunities for new drugs

CHAPTER 3 DRUGS IN DEVELOPMENT
3.1 Overview
3.2 Dopaminergic drugs
3.2.1 Agents which enhance basal dopamine levels or act as replacement therapies
3.2.1.1 Brasofensine
3.2.1.2 BTS-74398
3.2.1.3 CHF-1301
3.2.1.4 CHF-1512
3.2.2 Dopamine agonists
3.2.2.1 ABT-431
3.2.2.2 Apomorphine
3.2.2.3 Etilevodopa
3.2.2.4 PNU-95666
3.2.2.5 SPM-962
3.2.3 Inhibitors of monoamine oxidase
3.2.3.1 Lazabemide
3.2.3.2 Rasagiline
3.3 Cholinergic drugs
3.3.1 SIB-1508Y
3.4 Modulators of excitatory amino acid transmission
3.4.1 KW-6002
3.4.2 LY-300164
3.4.3 Remacemide
3.4.4 Riluzole
3.5 Neuroprotectives and other agents
3.5.1 Nitrone-related therapeutics
3.5.2 OPC-14117
3.6 Growth factors, genes and neurones
3.6.1 Glial cell-line derived neurotrophic factor
3.6.2 Brain-derived neurotrophic growth factor
3.6.3 NeuroCell-PD and NeuroCell-HD
3.6.4 NT-3
3.6.5 NIL-A
3.7 Miscellaneous agents
3.8 Neuroleptics and antipsychotics
3.8.1 Clozapine
3.8.2 Olanzapine
3.9 Summary of new approaches
3.10 Research with future potential
3.10.1 Foetal implants
3.10.2 Early research

REFERENCES

LIST OF TABLES
Table 1.1 Worldwide Parkinson's disease incidence and prevalence figures for different age groups, 1995
Table 1.2 Parkinson's disease incidence figures in different regions, 1995
Table 1.3 Parkinson's disease incidence figures in areas with varying degrees of development, 1995

Table 2.1 Summary of marketed Parkinson's disease drug classes and their mechanism of action
Table 2.2 Summary of marketed dopaminergic drugs
Table 2.3 Summary of companies with marketed first indication antiparkinsonian drugs
Table 2.4 Summary of companies with marketed antiparkinsonian agents which are not first indication treatments

Table 3.1 Summary of antiparkinsonian agents registered and awaiting registration
Table 3.2 Summary of drugs in clinical development for Parkinson's disease
Table 3.3 Summary of drugs in clinical development for Parkinson's disease which are not antiparkinsonian agents as a first indication
Table 3.4 Summary of drugs in preclinical development for Parkinson's disease
Table 3.5 Summary of dopaminergic drugs in development for Parkinson's disease
Table 3.6 Summary of excitatory amino acid transmission modulators in clinical development for Parkinson's disease

LIST OF FIGURES
Figure 1.1 The synthesis of dopamine
Figure 1.2 The metabolic breakdown of dopamine
Figure 1.3 Schematic representation of the removal of dopamine from a synapse

This volume, Parkinson's Disease, is part of a series forming
Scrip's Complete Guide to CNS Disorders. The other volumes in this series are:
Volume 1: Market Overview (BS1024)
Volume 2: Alzheimer's Disease and Other Dementias (BS1025)
Volume 4: Depression and Bipolar Disorder (BS1027)
Volume 5: Schizophrenia and Other Psychoses (BS1028)
Volume 6: Anxiety (BS1029)

EXECUTIVE SUMMARY
The worldwide market for Parkinson's disease drugs was $700 million in 1997, accounting for 22% of neurology-related products, and is predicted to reach $1,500 million in 2002. The increase can be attributed to the growing global elderly population and because the Parkinson's disease rate increases with age.

There is an ongoing debate about the use of the current gold standard treatment - levodopa - and whether its use should be delayed in younger patients so as to avoid inevitable movement problems later on in treatment. New alternative treatments are being developed as monotherapies to postpone the need for levodopa treatment and as adjunctive compounds to reduce the dosage of levodopa required, both with the common goal of preventing the 'on-off' fluctuations characteristic of lengthy treatment with levodopa. Other compounds on the market include the dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors and monoamine oxidase inhibitors.

Recent setbacks involving serious side effects with Roche's COMT inhibitor Tasmar (tolcapone), have left scope for improvement in this area, a gap which competitor companies are already attempting to fill. Again, there are opportunities for more convenient drug formulations. This is because the nature of Parkinson's disease means that swallowing an oral formulation can be difficult for some patients and so other options are required.

Alternative strategies are also being employed such as dopamine reuptake inhibitors, glutamate antagonists, adenosine A2 antagonists, iron chelating agents and the use of levodopa prodrugs. More excitingly, although in its early stages, are techniques which could revolutionise the way Parkinson's disease is treated by attempting to reverse the neurodegeneration itself, rather than just treating the symptoms of it.